Tango Therapeutics opened lower at $25.33, compared with its previous close of $25.73. In the last trading session, the stock traded between $23.60 and $25.37. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Tango Therapeutics is now worth
$ 191.60
Giving a profit of
$ 91.60 (91.60%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
85.71%
Hold
14.29%
Sell
0%
Markets Today
Today's Change
$-0.88 (-3.42%)
Day High
$25.37
Day Low
$23.60
Day Open
$25.33
Prev Close
$25.73
Volume
28,38,020
1W Return
7.23%
1M Return
2.72%
3M Return
-5.61%
6M Return
5.83%
1Y Return
196.54%
Fundamentals
Market Cap ($ Mn)
4,211
PE Ratio
-
PB Ratio
3.84
PEG Ratio
-
ROE
-50.42%
ROCE
-41.78%
EPS (TTM)
$-0.40
Investment Returns
1 Week
7.23%
1 Month
2.72%
3 Months
-5.61%
6 Months
5.83%
9 Months
97.07%
Financials
Quarterly
All values in $ Mn
3.2
Jun 25
53.8
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
11Nov
JP Morgan raises Tango Therapeutics price target to $47, keeps Overweight
JP Morgan raised Tango Therapeutics' price target to $47 from $46. The rating remains Overweight. Analyst Brian Cheng made the revision.
2 days ago
10Nov
HC Wainwright lowers Tango Therapeutics price target to $67
HC Wainwright & Co. maintains a Buy rating on Tango Therapeutics. Price target lowered from $68 to $67 by analyst Robert Burns. Rating remains unchanged despite the reduction in target price.
2 days ago
9Nov
Tango Therapeutics Q3 EPS of $(0.39) misses estimate by 11.43%
Tango Therapeutics reported a Q3 EPS of $(0.39), missing the consensus estimate of $(0.35) by 11.43%. The result marks a 378.57% decrease from the $0.14 EPS recorded in the same period last year. The company shifted from profitability to a net loss on a per-share basis year-over-year.
3 days ago
16Oct
Tango Therapeutics to present updated vopimetostat data at ESMO 2026
Tango Therapeutics to present updated Phase 1/2 data on vopimetostat combinations at ESMO Congress 2026. Poster presentation scheduled for October 25, 2026, with data cutoff as of April 3, 2026. Dedicated PDAC investor webcast set for October 23, 2026, at 7:30 am ET. Study focuses on MTAPdel/RASmut metastatic PDAC and NSCLC patients.
27 days ago
1Sep
Tango Therapeutics to hold fireside chat at 2026 Cantor Healthcare Conference
Tango Therapeutics management to speak at 2026 Cantor Global Healthcare Conference. Fireside chat scheduled for September 9, 2026, at 8:35 am EDT. Live webcast available via company investor relations page. Replay archived for 90 days post-event.
2mo ago
12Aug
Tango Therapeutics files prospectus for up to $400M common stock offering
Tango Therapeutics files prospectus for up to $400M common stock offering via Leerink Partners, terminating prior $100M facility where ~$64.4M was sold. Stock closed at $27.67 on Aug 10, 2026.
